坦洛新联合托特罗定治疗前列腺增生合并逼尿肌不稳定

发布时间：2018-05-22 08:24

本文选题：坦洛新 + 托特罗定　；参考：《青海大学》2014年硕士论文

【摘要】：目的：研究坦洛新（tamsulosion）与托特罗定（tolterodine）治疗前列腺增生合并逼尿肌不稳定(benign prostatic hyperplasia,BPH)，坦洛新与托特罗定单独用药对比两种药物联合用药在前列腺增生合并逼尿肌不稳定的治疗与预后的效果分析。方法：收集前列腺增生合并逼尿肌不稳定患者91例作为研究对象，（依据坦洛新和托特罗定联合用药与单独用药）将其分为3组，在3组中进行比较。每组研究对象就诊前分别测定前列腺症状国际评分（I-PSS）、膀胱过度活动症评分（OABSS）、膀胱残尿量(RUV)、最大尿流率（QMAX）。实验组每日口服坦洛新胶囊，0.2mg/次，每日1次，每日口服托特罗定片，2mg/次，每日2次。治疗12周后再次复查上述四项指标。对照组A每日口服坦洛新胶囊，0.2mg/次，每日1次，治疗12周后再次复查上述四项指标。对照组B每日口服托特罗定片，2mg/次，每日2次，治疗12周后复查上述四项指标。结果：实验组患者治疗12周后I-PSS评分、OABSS评分、RUV、QMAX分别为（11.3±2.0）,(1.7±0.4),(19.6±4.1),(16.3±3.9)。对照组A患者治疗12周后I-PSS评分、OABSS评分、RUV、QMAX分别为（16.2±2.1）,(3.6±0.6),(19.1±3.7),(15.1±2.1)。对照组B患者治疗12周后I-PSS评分、OABSS评分、RUV、QMAX分别为（17.2±2.1）,(3.6±0.7),(35.7±3.9),(11.1±3.1)。实验组患者治疗后上述前列腺相关指标明显改善，其数据与对照组比较有统计学差异（P0.05）。结论：坦洛新联合托特罗定治疗前列腺增生合并逼尿肌不稳定效果显著，可明显改善患者储尿期下尿路症状及患者生活质量。托特罗定适当剂量用药不会影响逼尿肌排尿功能。
[Abstract]:Objective: to study the effects of Thaloxine and tolterodine in the treatment of prostatic hyperplasia with detrusor instability, tenlosin and tolterodine alone in the treatment of prostatic hyperplasia with detrusor instability. Effect analysis of treatment and prognosis. Methods: 91 patients with benign prostatic hyperplasia complicated with detrusor instability were divided into 3 groups. The international score of prostatic symptoms (I-PSSN), bladder hyperactivity score (OABSS), bladder residual urine volume (RUVN), and maximal urinary flow rate (MVF) were measured before treatment. The experimental group was treated with Thaloxin capsule 0.2 mg / d once a day and Totterodine 2 mg / d twice a day. After 12 weeks of treatment, the above four indexes were reviewed again. The control group A was treated with 0.2 mg / d Tanluoxin capsule once a day. After 12 weeks of treatment, the above four indexes were reviewed again. Control group B was treated with toterodine 2mg / d, twice a day. After 12 weeks of treatment, the above four indexes were reviewed. Results: after 12 weeks of treatment, the I-PSS scores and the RUV QMAX of the patients in the experimental group were 11.3 卤2.0 and 1.7 卤0.4, respectively, and were 19.6 卤4.1 and 16.3 卤3.9 respectively. In the control group, the I-PSS score and the I-PSS score were 16.2 卤2.1 and 3.6 卤0.6 respectively after 12 weeks of treatment, and the I-PSS scores were 19.1 卤3.7 and 15.1 卤2.1 respectively. In the control group, the I-PSS score and the I-PSS score were 17.2 卤2.1, 3.6 卤0.7, 35.7 卤3.9 and 11.1 卤3.1 respectively after 12 weeks of treatment in the control group. Compared with the control group, the patients in the experimental group improved the above prostatic index significantly, and the data were significantly different from that of the control group (P 0.05). Conclusion: Thaloxin combined with tolterodine is effective in the treatment of benign prostatic hyperplasia with detrusor instability, and can improve the symptoms of the lower urinary tract and the quality of life of the patients. Proper dosage of tolterodine does not affect detrusor urination function.
【学位授予单位】：青海大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R697.3

【参考文献】